Abbott's continuous glucose monitoring (cgm) growth is reportedly ongoing, despite some moderation in the first quarter. The company's medical device strategy and technological innovations, including expansion on the android platform and new glucose-ketone monitors, are seen as supporting long-term growth. Other companies in the field, such as dexcom, have also been mentioned in the context of the story, but their specific roles are unclear.